Bangkok Genomics Innovation PCL (BKK:BKGI) Short-Term Debt: ฿0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:BKGI Bangkok Genomics Innovation PCL BKK:BKGI
45 GF Score
Price ฿2.36
! 12 Warning Signs
View Full Analysis

What is Bangkok Genomics Innovation PCL Short-Term Debt?

Bangkok Genomics Innovation PCL BKK:BKGI 45 Short-Term Debt is ฿0.0 Mil as of Dec. 2025. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review.

Bangkok Genomics Innovation PCL's Short-Term Debt for the quarter that ended in Dec. 2025 was ฿0.0 Mil.

Bangkok Genomics Innovation PCL Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Bangkok Genomics Innovation PCL Short-Term Debt Related Terms

Bangkok Genomics Innovation PCL Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Bangkok Genomics Innovation PCL's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bangkok Genomics Innovation PCL Short-Term Debt Chart

Bangkok Genomics Innovation PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Bangkok Genomics Innovation PCL Quarterly Data
Dec19 Dec20 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BKK:BKGI
45GF Score
Bangkok Genomics Innovation PCL BKK:BKGI
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ฿0.0 Mil mean?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a Short-Term Debt of ฿0.0 Mil as of Dec. 2025.
Is Bangkok Genomics Innovation PCL's Short-Term Debt too high?
Bangkok Genomics Innovation PCL's current Short-Term Debt is ฿0.0 Mil. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's Short-Term Debt compare to TMO and DHR?
Bangkok Genomics Innovation PCL's Short-Term Debt of ฿0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Diagnostics & Research company?
A good Short-Term Debt depends on the Medical Diagnostics & Research industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Bangkok Genomics Innovation PCL's current Short-Term Debt is ฿0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current Short-Term Debt of ฿0.0 Mil. The current Short-Term Debt is ฿0.0 Mil. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current Short-Term Debt is ฿0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bangkok Genomics Innovation PCL Business Description

Address 3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score

Get the complete analysis for BKK:BKGI

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿2.36
Price